Cantor Fitzgerald raised its price target for Ascendis Pharma to $203, citing strong Q2 revenue from Yorvipath. Other firms like RBC Capital and Evercore ISI also raised their targets, reflecting bullish sentiment.

Evercore ISI raised its price target for Ascendis Pharma (NASDAQ:ASND) to $285 from $280, maintaining an Outperform rating. The company's stock surged 9.1% in the past week, driven by strong performance in its Yorvipath product. Goldman Sachs also raised its price target to $250, citing robust sales of Yorvipath. Ascendis reported a narrower-than-expected second-quarter loss but exceeded revenue estimates, with a 339% year-over-year revenue increase.

TD Cowen raised its price target on Ascendis Pharma (NASDAQ: ASND) to $227.00 from $194.00, citing strong Yorvipath performance and positive outlook for future trials. The company, valued at $11.5 billion, saw shares rise 57% in six months. Yorvipath showed 77% QoQ growth in patient start forms, while Skytrofa faced FX headwinds but expects improvement. The firm anticipates Phase 2 data in Q4 2025 and highlights robust Q2 revenue of EUR158.05M, surpassing expectations.

BofA Securities raised its price target on Ascendis Pharma (NASDAQ:ASND) to $227 from $217 while maintaining a Buy rating, citing strong second-quarter results. The company reported €103 million in revenue, exceeding expectations, and expects continued growth with a 2032 peak year projection. Analysts including Evercore ISI and Goldman Sachs also raised their price targets, reflecting confidence in the company's performance.

BofA Securities raised its price target on Ascendis Pharma from $217 to $227 while maintaining a 'Buy' rating. The adjustment follows recent positive earnings reports and FDA approvals for the company's drugs.